Last updated: 11/19/2026 12:20:13

A study of Cobolimab plus Dostarlimab in pediatric and young adult participants with cancer

GSK study ID
219451
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
Trial description: The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Primary purpose:
Treatment
Trial design:
Sequential Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:

Part 1: Number of participants with Dose Limiting Toxicities (DLTs)

Timeframe: Up to 42 days

Part 1: Number of participants with any treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

Timeframe: Up to approximately 62 weeks

Part 1: Number of participants with immune-mediated adverse events (imAEs)

Timeframe: Up to approximately 62 weeks

Part 1: Number of participants with AEs leading to discontinuation of study treatment

Timeframe: Up to approximately 62 weeks

Part 1: Serum concentration of Cobolimab

Timeframe: Cycle(C)1 Day(D)1:1hour(h) post-dose;C1D8:168h post-dose;C2 D1,C4 D1,C6 D1:Pre-dose and 1h post-dose;End of Treatment:Within 7days of last dose(Anytime up to a maximum of 62weeks);Safety Follow-up:30days after lastdose(Anytime up to a maximum of 62weeks)

Part 1: Serum concentration of Dostarlimab

Timeframe: Cycle1 Day1:1h post-dose; Cycle2 Day1, Cycle4 Day1, Cycle6 Day1:Pre-dose; End of Treatment: Within 7days of lastdose(Anytime up to a maximum of 62weeks);Safety Follow-up:30days after last dose(Anytime up to a maximum of 62weeks); each cycle is of 21 days

Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab

Timeframe: Up to approximately 12 months

Part 2: Confirmed Objective Response Rate (ORR)

Timeframe: Up to approximately 62 weeks

Part 2: Number of participants with TEAEs and TESAEs

Timeframe: Up to approximately 62 weeks

Part 2: Number of participants with immune-mediated adverse events (imAEs)

Timeframe: Up to approximately 62 weeks

Part 2: Number of participants with TEAEs leading to death and AEs leading to discontinuation of study treatment

Timeframe: Up to approximately 62 weeks

Part 2: Number of Participants with worst case hematology results relative to normal range post-baseline relative to baseline

Timeframe: Up to approximately 62 weeks

Part 2: Number of Participants with worst case clinical chemistry results relative to normal range post-baseline relative to baseline

Timeframe: Up to approximately 62 weeks

Part 2: Number of Participants with worst case vital signs results relative to normal range post-baseline relative to baseline

Timeframe: Up to approximately 62 weeks

Part 2: Number of participants with worst case Electrocardiogram (ECG) results relative to normal range post-baseline relative to baseline

Timeframe: Up to approximately 62 weeks

Secondary outcomes:

Part 1: T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) receptor occupancy (free-to-total TIM-3 receptor ratio) of cobolimab

Timeframe: Cycle 1 Day 1: Pre-dose and 5 hours post-dose; Cycle1 Day8: Anytime; Cycle 2 Day 1: Pre-dose; Cycle 4 Day1: Pre-dose; each cycle is of 21 days

Part 1: Confirmed Objective Response Rate (ORR)

Timeframe: Up to approximately 62 weeks

Part 1: Progression Free Survival (PFS)

Timeframe: Up to approximately 62 weeks

Part 1: Duration of Response (DOR)

Timeframe: Up to approximately 62 weeks

Part 1: Overall Survival (OS)

Timeframe: Up to approximately 62 weeks

Part 1: Number of Participants With Post-Baseline Positive Anti-drug Antibodies (ADAs) against cobolimab

Timeframe: Up to approximately 62 weeks

Part 1: Number of Participants With Post-Baseline Positive ADAs against dostarlimab

Timeframe: Up to approximately 62 weeks

Part 1: Titers of ADAs against cobolimab

Timeframe: Up to approximately 62 weeks

Part 1: Titers of ADAs against dostarlimab

Timeframe: Up to approximately 62 weeks

Part 2: Progression Free Survival (PFS)

Timeframe: Up to approximately 62 weeks

Part 2: Duration of Response (DOR)

Timeframe: Up to approximately 62 weeks

Part 2: Overall Survival (OS)

Timeframe: Up to approximately 62 weeks

Part 2: Serum concentration of Cobolimab

Timeframe: C1 D1:1hour post-dose; C2 D1, C4 D1, C6 D1:Pre-dose and 1h post-dose; End of Treatment: Within 7days of last dose(Anytime up to a maximum of 62 weeks); Safety Follow-up:30days after last dose(Anytime up to a maximum of 62 weeks); each cycle is of 21 days

Part 2: Serum concentration of Dostarlimab

Timeframe: C1 D1: 1 hour post-dose; C2 D1, C4 D1, C6 D1: Pre-dose; End of Treatment: Within 7days of last dose (Anytime up to a maximum of 62 weeks); Safety Follow-up:30days after last dose (Anytime up to a maximum of 62 weeks); each cycle is of 21 days

Part 2: TIM-3 receptor occupancy of cobolimab

Timeframe: Cycle 1 Day 1: Pre-dose and 5 hours post-dose; Cycle 2 Day 1, Cycle 4 Day 1: Pre-dose; each cycle is of 21 days

Part 2: Number of Participants With Post-Baseline Positive ADAs against cobolimab

Timeframe: Up to approximately 62 weeks

Part 2: Number of Participants With Post-baseline Positive ADAs against dostarlimab

Timeframe: Up to approximately 62 weeks

Part 2: Titers of ADAs against cobolimab

Timeframe: Up to approximately 62 weeks

Part 2: Titers of ADAs against dostarlimab

Timeframe: Up to approximately 62 weeks

Interventions:
Drug: Cobolimab
Drug: Dostarlimab
Enrollment:
12
Primary completion date:
2026-18-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma multiforme (GBM), Diffuse intrinsic pontine glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic tumors, Hepatoblastoma, Hepatocellular carcinoma (HCC), Fibrolamellar carcinoma, Rhabdomyosarcoma
Product
Not applicable
Collaborators
Not applicable
Study date(s)
March 2025 to May 2026
Type
Interventional
Phase
1/2

Participation criteria

Sex
Female & Male
Age
0 - 21 Years
Accepts healthy volunteers
No
  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participants between the age of 0 to not more than 21 years at the time of signing informed consent form (ICF).
  • Participants are excluded from the study if any of the following criteria apply:
  • Medical conditions:

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Iowa City, IA, United States, 52242
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, OH, United States, 45229
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, CA, United States, 90048
Status
Study Complete
Location
GSK Investigational Site
Barcelona, Spain, 08035
Status
Study Complete
Location
GSK Investigational Site
Copenhagen, Denmark, 2100
Status
Study Complete
Location
GSK Investigational Site
MADRID, Madrid, Spain, 28009
Status
Study Complete
Location
GSK Investigational Site
Valencia, Spain, 46026
Status
Study Complete
Location
GSK Investigational Site
MADRID, Madrid, Spain, 28046
Status
Study Complete
Location
GSK Investigational Site
Phaha 5, Unmapped, 15006
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Providence, RI, United States, 02903-4923
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Napoli, Italy, 80123
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bologna, Italy, 40138
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hackensack, NJ, United States, 07601
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Brno, Unmapped, 61300
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Madison, WI, United States, 53792-0001
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Paris cedex 5, France, 75248
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bordeaux, France, 33076
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Strasbourg Cedex, France, 67098
Status
Terminated/Withdrawn
Location
GSK Investigational Site
LYON CEDEX 08, France, 69373
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Villejuif cedex, France, 94805
Status
Terminated/Withdrawn

Study documents

Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2026-18-05
Actual study completion date
2026-18-05

Plain language summaries

Summary of results in plain language
Available language(s): English, Danish, Spanish

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website